Dyne's stock has exhibited significant volatility, with a 52-week range of $8.88 to $25.00 and a market capitalization of approximately $3.92 billion as of July 19, 2026. The company remains pre-revenue, with widening losses and no near-term profitability. The offering's completion is not guaranteed; it depends on market conditions and final SEC documentation. The interplay between dilution mechanics and the binary outcome of the January 2027 FDA decision now defines the investment calculus. With the runway extended but the share count set to rise, the central question is whether the market will price the dilution fully before the regulatory catalyst has a chance to revalue the asset.
Sources: Source 1 · Source 2 · Source 3 · Source 4 · Source 5 · Source 6
